ロードアイランドにおける多発性骨髄腫の臨床試験
ロードアイランド内の拠点で、多発性骨髄腫に関する6件の研究が参加者を募集しています。
ロードアイランド内の都市
公式研究テキスト（英語）
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Rhode Island Hospital, Providence
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Rodhe Island Hospital, Providence
- The Miriam Hospital, Providence
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Smilow Cancer Hospital Care Center - Westerly, Westerly
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Smilow Cancer Hospital Care Center - Westerly, Westerly
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Providence
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Rhode Island Hospital, Providence
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/06/03更新 · NCT06119685ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。